Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

11/12/24 9:55:15 AM ET

Other Consumer Services

Consumer Discretionary

Get the next $EVH alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 EVOLENT HEALTH INC CLASS A COMMON STOCK Cusip #30050B101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #30050B101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,519,033 Item 6: 0 Item 7: 4,522,994 Item 8: 0 Item 9: 4,522,994 Item 11: 3.883% Item 12: HC Cusip #30050B101 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,522,994 Item 8: 0 Item 9: 4,522,994 Item 11: 3.883% Item 12: IN Item 1(a). Name of Issuer: EVOLENT HEALTH INC Item 1(b). Address of Issuer's Principal Executive Offices: 800 NORTH GLEBE RD, Suite 500 Arlington, VA 22203 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: CLASS A COMMON STOCK Item 2(e). CUSIP Number: 30050B101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 4,522,994 (b) Percent of Class: 3.883% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,522,994 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of EVOLENT HEALTH INC. No one other person's interest in the CLASS A COMMON STOCK of EVOLENT HEALTH INC is more than five percent of the total outstanding CLASS A COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the CLASS A COMMON STOCK of EVOLENT HEALTH INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $EVH alert in real time by email

Recent Analyst Ratings for

$EVH

Date	Price Target	Rating	Analyst
1/10/2025	$15.00	Buy	Needham
12/3/2024	$36.00 → $29.00	Buy	BTIG Research
11/8/2024	$38.00 → $16.00	Overweight → Equal-Weight	Stephens
10/11/2024	$35.00	Overweight	KeyBanc Capital Markets
8/9/2024	$28.00 → $33.00	Hold → Buy	Truist
4/22/2024	$40.00	Buy	Citigroup
3/1/2024	$45.00	Outperform	Oppenheimer
1/3/2024	$39.00	Overweight	Barclays

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

11/12/24 9:55:15 AM ET

$EVH

Other Consumer Services

Consumer Discretionary

Get the next $EVH alert in real time by email

Recent Analyst Ratings for

$EVH

Date	Price Target	Rating	Analyst
1/10/2025	$15.00	Buy	Needham
12/3/2024	$36.00 → $29.00	Buy	BTIG Research
11/8/2024	$38.00 → $16.00	Overweight → Equal-Weight	Stephens
10/11/2024	$35.00	Overweight	KeyBanc Capital Markets
8/9/2024	$28.00 → $33.00	Hold → Buy	Truist
4/22/2024	$40.00	Buy	Citigroup
3/1/2024	$45.00	Outperform	Oppenheimer
1/3/2024	$39.00	Overweight	Barclays

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$EVH

Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$EVH

$EVH
SEC Filings

Evolent Health Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

SEC Form 8-K filed by Evolent Health Inc

SEC Form 8-K filed by Evolent Health Inc

$EVH
Press Releases

Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

Evolent Announces Second Quarter 2025 Results

$EVH
Insider Purchases

Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

Director Jelinek Richard M bought $273,750 worth of shares (30,000 units at $9.12) (SEC Form 4)

$EVH
Analyst Ratings

Needham initiated coverage on Evolent Health with a new price target

BTIG Research reiterated coverage on Evolent Health with a new price target

Evolent Health downgraded by Stephens with a new price target

$EVH
Insider Trading

Chief Accounting Officer Shams Aammaad covered exercise/tax liability with 2,567 shares, decreasing direct ownership by 3% to 72,899 units (SEC Form 4)

Chief Executive Officer Blackley Seth was granted 67,150 shares, increasing direct ownership by 9% to 829,367 units (SEC Form 4)

General Counsel Weinberg Jonathan was granted 23,394 shares, increasing direct ownership by 10% to 254,179 units (SEC Form 4)

$EVH
Leadership Updates

Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

Define Ventures Appoints Carolyn Magill as Venture Partner

Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

$EVH
Financials

Evolent Announces Second Quarter 2025 Results

Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Evolent reiterates Q2 and full year guidance for Adjusted EBITDA

$EVH
Large Ownership Changes